文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

COVID-19出院患者6个月后果:一项队列研究

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
PubMed 文献 · Lancet · 2021-01-08
一句话结论COVID-19出院患者6个月时常见疲劳/肌无力、睡眠困难和焦虑/抑郁,病情越重者肺弥散功能受损和影像异常越明显。

该双向队列研究纳入武汉金银潭医院2020年1月7日至5月29日出院的1733例COVID-19确诊患者,中位随访186天。疲劳或肌无力(63%)和睡眠困难(26%)最常见,焦虑或抑郁占23%。重症患者是长期康复干预的主要目标人群。

要点

  • 出院6个月时疲劳或肌无力最常见(63%,1038/1655),其次为睡眠困难(26%,437/1655)和焦虑或抑郁(23%,367/1617)。
  • 病情越重者弥散功能受损比例越高:7分类量表3分22%、4分29%、5-6分56%。

适用人群与场景

  • 2020年1月7日至5月29日从武汉金银潭医院出院的COVID-19确诊患者,最终纳入1733例(2469例中排除736例)。
  • 排除标准包括:随访前死亡、因精神障碍/痴呆/再入院而随访困难、因骨关节病或卒中/肺栓塞等无法自由活动、拒绝参与、无法联系、居住在武汉以外或养老/福利机构者。

诊断标准与关键阈值

  • 采用7分类量表(highest seven-category scale)在住院期间分层为3、4、5-6分,按此分层抽样部分患者接受肺功能、高分辨率CT和超声检查。
  • 6分钟步行距离低于正常范围下限、弥散功能受损、CT评分、焦虑/抑郁、疲劳/肌无力为随访评估指标。
  • 原文未提及诊断标准的具体界值或评分定义。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 最常见症状:疲劳或肌无力63%(1038/1655),睡眠困难26%(437/1655),焦虑或抑郁23%(367/1617)。

证据类型、等级与局限

  • 研究类型:双向队列研究(ambidirectional cohort study),单中心。
  • 证据等级:原文未提及。
  • 局限性:单中心、观察性设计;部分分析基于分层抽样;抗体检测仅94例;随访6个月,不能反映更长期结局。

对床旁实践的改变

  • 对COVID-19出院患者,尤其住院期间病情较重(7分类量表5-6分)者,6个月随访应关注疲劳/肌无力、睡眠困难、焦虑/抑郁症状及肺弥散功能。
  • 重症患者肺弥散功能受损和胸部CT异常比例更高,是长期康复干预的主要目标人群。
  • 随访时需注意中和抗体水平较急性期下降,以及急性期无AKI者随访时可能出现eGFR下降。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.

METHODS: We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5-6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences.

FINDINGS: In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0-65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0-199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5-6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5-6, and median CT scores were 3·0 (IQR 2·0-5·0) for severity scale 3, 4·0 (3·0-5·0) for scale 4, and 5·0 (4·0-6·0) for scale 5-6. After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up.

INTERPRETATION: At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery.

FUNDING: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021. PMID: 33428867. doi:10.1016/S0140-6736(20)32656-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。